WO2003053473A2 - Ph-sensitive polymeric conjugates of an anthracycline drug - Google Patents
Ph-sensitive polymeric conjugates of an anthracycline drug Download PDFInfo
- Publication number
- WO2003053473A2 WO2003053473A2 PCT/CZ2002/000070 CZ0200070W WO03053473A2 WO 2003053473 A2 WO2003053473 A2 WO 2003053473A2 CZ 0200070 W CZ0200070 W CZ 0200070W WO 03053473 A2 WO03053473 A2 WO 03053473A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acids
- polymeric
- conjugates
- units
- oligopeptides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- pH-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy pH-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy
- the invention involves polymeric anti-cancer drugs which enable targeted transport in the body and are focused on targeted tumor therapy in human medicine.
- the anti-cancer drug in such substances is attached to a polymeric N-(2- hydroxypropyl)methacrylamide carrier by an enzyme-cleavable oligopeptide sequence, prepared as a substrate for lysosome enzymes (enzymes present in mammalian cells).
- enzyme-cleavable oligopeptide sequence prepared as a substrate for lysosome enzymes (enzymes present in mammalian cells).
- the structure, synthesis and properties of such conjugates have been described in a patent [Duncan 1985].
- the results obtained in this area up to now have been clearly summarized by Kopecek et al [Kopecek et al 2000].
- the above polymeric drugs have been effective in the treatment of a number of tumors in mice and rats. At present, two of the polymeric conjugates are even being tested clinically.
- conjugates either contain no targeting unit at all, such as PK1, or contain a carbohydrate of a relatively low specificity (galactosamine in the PK2 conjugate in which the ability to direct a polymeric drug to the liver is being tested). Therefore, conjugates in which the aimed specific effect is achieved by attaching a specific targeting molecule (e.g. antibodies, as well as lectin, the growth hormone, transferin, etc.) to the carrier molecule are being developed.
- a specific targeting molecule e.g. antibodies, as well as lectin, the growth hormone, transferin, etc.
- Another disadvantage of the clinically tested conjugates including those of poly(HPMA) and doxorubicin, is the fact that the drug in its pharmacologically active form is only released from such conjugates in cells by an enzymatic reaction which occurs in lysosomes. This means that the drug is only effective in cells with a high concentration of lysosome enzymes - peptidases.
- Another disadvantage is a relatively complex structure of the conjugate requiring the inclusion of a sequence from which the drug is released by peptidases, mostly the GlyPheLeuGly tetrapeptide link, which makes the synthesis more expensive and complicated.
- the polymeric cancerostatic drugs developed by us and prepared on the basis of copolymers of HPMA and a cancerostatic drug linked by a pH-sensitive hydrazone bond have shown, in both in vitro and in vivo tests in mice, a significantly higher anti-tumor efficacy in relation to a number of tumor lines compared to conjugates with the drug attached to the polymeric carrier by an enzyme-cleavable bond via an oligopeptide link.
- the synthesis of such conjugates compared with the poly(HPMA) conjugates developed earlier is more simple, less expensive and easier to manage since one amino acid only can be used as a link instead of the enzyme-degradable oligopeptide sequence and bonding of the drug to the polymer is a simple reaction.
- the drug is released as a result of a change of pH in the medium and therefore the presence of lysosome enzymes is not essential for activation.
- the rate of such release (and therefore the immediate cytostatic concentration) is much higher compared to conjugates containing sequences only degradable by enzymes. [Rihova et al, 2001, Etrych et al, 2001].
- the invention provides linear and branched polymeric conjugates of doxorubicin, daunomycin, pharmorubicin and other anthracycline cancerostatic drugs containing a carbonyl group with copolymers prepared on the basis of N-(2-hydroxypropyl)-methacrylamide (HPMA) and optionally with antibodies, their fragments or non-specific immunoglobulin (Fig. 3). It is characteristic for these conjugates that the polymeric carrier along with the antibody (immunoglobulin) ensures prolonged circulation of the polymeric drug in blood vessels and its subsequent preferred passive or active accumulation in the tumor.
- the anti-cancer drug is attached to the carrier by a bond stable in the blood vessels (at pH 7.4).
- the cancerostatic loses its biological effect and is transported by the blood vessels in its inactive form.
- the cytotoxic drug only becomes activated intracellularly, in the organelles of the target cells, as pH decreases and the bond between the drug and the polymer is hydrolyzed.
- the conjugates comprise a polymeric carrier formed by 30 to 3,000 monomer units linked to form a polymeric chain, 60 to 99 % of them being constituted by N-(2- hydroxypropyl)methacrylamide units, 1 to 25 % of them being the units of methacryloylated hydrazones of ⁇ -amino acids, ⁇ -amino acids, aromatic amino acids or oligopeptides terminated by an anthracycline cancerostatic molecule (preferably doxorubicin) and 0.5 to 15 % being the units of methacryloylated ⁇ -amino acids, ⁇ -amino acids, aromatic amino acids or oligopeptides or their sodium salts; optionally, 0.5 to 10 % units of methacryloylated hydrazides of ⁇ -amino acids, ⁇ -amino acids, aromatic amino acids or oligopeptides are included and the conjugate may optionally include 0.5 to 5 % of methacryloylated ⁇
- the branched macromolecular structures also contain 0.1 to 5 % of units forming links that interconnect the individual polymeric chains to form the branched macromolecular structure, which links consist of enzyme-degradable methacryloylated oligopeptides, preferably tripeptides GlyPheGly, GlyLeuGly or tetrapeptide GlyPheLeuGly, interconnected by diamines (ethylene diamine, hexamethylene diamine).
- links consist of enzyme-degradable methacryloylated oligopeptides, preferably tripeptides GlyPheGly, GlyLeuGly or tetrapeptide GlyPheLeuGly, interconnected by diamines (ethylene diamine, hexamethylene diamine).
- a characteristic of the polymeric conjugates with targeted anti-tumor action of this invention is the linkage between the active component - cytostatic - and the polymeric carrier via a hydrazone group formed in the reaction between the carbonyl group of the drug molecule and the polymer's hydrazide group.
- the linkage of the drug to the polymeric carrier significantly increases the drug's molecular weight resulting in prolonged time of circulation in the blood and of total retention time of the active component in the body.
- the linkage between the drug and the polymer is relatively stable during the drug transport in the blood vessels and hydrolytically cleavable in the slightly acidic environment inside the cells, namely in cellular organelles characterized by acidic pH.
- a polymeric carrier on the basis of HPMA copolymers is responsible for targeted transport to the tumor or tumor cells.
- HPMA high-molecular poly(HPMA) carrier
- the polymeric drug is stored in the solid tumor tissue due to passive targeting and the EPR effect (Enhanced Permeability and Retention effect).
- the polymer may be released from the body following enzymatic degradation of the oligopeptide links in the form of shorter polymeric chains, for example by glomerular filtration.
- the antibody In carriers containing antibodies (immunoglobulin) the antibody is attached to the carrier via a hydrazone bond formed in reaction between the aldehyde groups, incorporated into an Fc fragment of the antibody by sodium periodate oxidation, and the carrier's hydrazone groups.
- the antibody (immunoglobulin) may also be attached to the polymeric carrier chain using bifunctional agents.
- the antibody molecule is modified by reacting with 2-iminothiolane (introduction of -SH groups), maleimide groups are introduced into the polymer by reacting its hydrazide groups with succinimide ester of 3-maleimide propionic acid and the conjugation then occurs by addition of the -SH group of the antibody to the double bond of the polymer's maleimide group.
- the conjugation may also be initiated by another bifunctional agent, such as SPDP (N-hydroxysuccinimide ester of 3-(2-pyridyldithio) propionic acid), which can be used to conjugate an -SH group containing antibody (immunoglobulin) directly to the hydrazide groups of the polymeric carrier.
- SPDP N-hydroxysuccinimide ester of 3-(2-pyridyldithio) propionic acid
- the conjugate with the antibody is accumulated in the target organs/tissues both passively and actively. Passive accumulation is enabled by the higher molecular weight of the conjugate and involves the so-called EPR effect, active accumulation is ensured by a process in which the binding site of the targeting antibody interacts with relevant receptors on the surface of the target cells. In the latter case the HPMA copolymer plays the role of both the carrier and a protective wrap significantly reducing immunogenicity of the targeting glycoprotein in the conjugate.
- the polymeric drug according to this invention can be used in three forms differing in their detailed structure.
- the first structure is represented by a linear polymeric conjugate with the drug without the targeting antibody (immunoglobulin) (Fig. 1); the second one is high molecular and represents a branched polymeric structure with biodegradable oligopeptide links (Fig. 2).
- the third structure includes also the targeting molecule (immunoglobulin) (Fig. 3).
- Preparation of non-targeted linear polymeric drugs occurs in a plurality of reaction steps.
- the first step involves preparation of polymeric precursor I (see Fig. 4) as a copolymer of HPMA and methacryloylated reactive esters (4-nitrophenyl esters, N-hydroxysuccinimide esters, etc.) of amino acids or oligopeptides
- the second step leading to preparation of polymeric precursor II, involves hydrazinolytic transformation of the terminal ester groups to hydrazides.
- a cancerostatic containing a keto group in the molecule is attached to the hydrazide groups by a chemical hydrazone bond.
- Preparation of a branched polymeric drug needs to be started from polymeric precursor I containing an enzyme-degradable oligopeptide in its side chains, preferably GlyPheGly, GlyLeuGly, GlyPheLeuGly or GlyLeuPheGly.
- the second step is initiated by slight branching of the polymer by reacting polymeric precursor I and alkylene diamine (ethyl, butyl, hexyl) and terminated by subsequent hydrazinolysis with hydrazine hydrate as described in the previous case.
- Drugs targeted with antibodies can be prepared from both previous types of drugs by subsequent reaction with an antibody (immunoglobulin) into the structure of which aldehyde groups have been previously introduced by mild oxidation with KIO 4 or NaIO or by way of their conjugation with the antibody (immunoglobulin) using bifunctional agents as described above.
- This invention can be used to prepare polymeric drugs for the treatment of various types of tumors in human medicine. Brief Description of Drawings
- Fig. 1 shows the structure of a linear polymeric conjugate with a drug.
- Fig. 2 shows a branched macromolecular structure of a polymer with biodegradable oligopeptide links.
- Fig. 3 shows the structure of a conjugate including the taregting antibody.
- Fig. 4 shows a polymeric precursor
- Fig. 5 shows the measurement results of the release rate of doxorubicin from the conjugates of this invention.
- Fig. 6 shows the result of comparison of in vitro inhibition activities of the conjugates of this invention bound by means of various links.
- Fig. 7 shows the result of comparison of in vivo inhibition activities of the conjugates of this invention bound by means of various links.
- Fig. 8 shows the results of in vivo studies of anti-tumor activities of the conjugates of this invention.
- Synthesis of the polymeric drug was made in four synthetic steps.
- the monomers N-(2-hydroxypropyl)methacrylamide (HPMA) and 4-nitrophenyl esters of a methacryloylated amino acid or oligopeptide (MA-X-ONp) were prepared.
- the second step was the preparation of polymeric precursor I by radical copolymerization of HPMA and MA- X-ONp.
- polymeric precursor II was prepared by hydrazinolysis of precursor I and in the last step linking of Dox to the polymeric precursor was effected.
- HPMA was prepared by the method as described previously [Ulbrich 2000].
- DCCI dicyclohexylcarbodiimide
- 4-Nitrophenyl ester was prepared by reacting 0.014 mol (2.85 g) N-methacryloyl 4-amino benzoic acid with 0.014 mol (1.93 g) 4-nitrophenol in dimethylformamide at -10 °C in the presence of 0.0153 mol (3.16 g) dicyclohexylcarbodiimide. The reaction ran for 10 hours after which the precipitated dicyclohexylurea was filtered off and the product was purified by crystallization from an acetone-water mixture.
- the other two 4-nitrophenyl esters (MA-X-O ⁇ p) can be prepared in an analogous way.
- the methacryloylated derivatives of GlyLeuGly, GlyPheGly, GlyPheLeuGly, ⁇ -alanine and ⁇ -amino caproic acid were also prepared by methacryloylation of oligopeptides or of an acid, however, following the acidification of the aqueous phase the methacryloylated acids had to be extracted into ethyl acetate and isolated by crystallization.
- the appropriate reactive esters (O ⁇ p esters) are prepared analogously as MA-AB-O ⁇ p except that the reaction medium for the esterification of MA-GlyLeuGly-OH and MA-GlyPheLeuGly-OH was tetrahydrofuran.
- polymeric precursor I 1 g of a mixture of HPMA (95 %mol, 0.89 g) and MA- AB-O ⁇ p (5 %mol, 0.11 g) and 0.048 g azo-bis-isobutyronitrile were dissolved in 6.95 g acetone and the solution was placed in a polymerization ampoule. After the polymerization mixture was bubbled with nitrogen the ampoule was sealed up and the polymerization carried out at 50 °C for 24 hours. The pecipitated polymer was filtered off, rinsed for three times with acetone and diethyl ether and vacuum dried.
- the content of side chains terminated with reactive -ONp groups can be controlled by the composition of the polymerization charge (the ratio of monomers).
- the same process was used to prepare all the polymeric precursors differing in the composition of the side chains.
- polymeric precursor II The poly(HPMA-co-MA-AB-NHNH 2 ) copolymer was prepared by reacting polymeric precursor I with hydrazine hydrate. 300 mg polymeric precursor I (1.3 x 10 "4 mol ONp) were dissolved in 2 ml methanol and a solution of 69 mg NH 2 NH 2 .H O in 1 ml methanol (1.3 x 10 "3 mol, 10 fold excess relative to ONp) was added under intensive stirring. The reaction mixture was left to react for 3 hours after which the methanol solution was diluted with distilled water to 30 ml and the product stripped of low- molecular components using dialysis against distilled water (2 days).
- the final product was isolated from the aqueous solution by lyophilization.
- the molecular weight (M w ) and polydispersity of the polymer were determined by means of gel chromatography equipped with a light dispersion detector.
- the amount of hydrazide groups was determined by spectroscopy following the reaction of hydrazide groups with TNBS (trinitrobenzenesulfonic acid).
- Precursors containing other amino acids and oligopeptides were prepared in the same manner.
- Polymeric precursors II were also prepared by radical precipitation copolymerization of the corresponding N-tert.
- the product was re-precipitated from methanol into diethyl ether and dried until constant weight.
- the content of Dox and hydrazide groups was determined by spectroscopy ( ⁇ 480 nm, ⁇ 11 500 L mol "1 cm “1 , water) and by TNBS, respectively.
- ⁇ M W > and molecular weight distribution were determined by liquid chromatography (SuperoseTM6 (300x10 mm) column, 0.3 M acetate buffer (CH 3 COONa CH 3 COOH; pH 6.5; 0.5 g/L NaN 3 ), flow rate 0.5 ml/min, detection by differential refractometer, light dispersion detector (DAWN-DSP-F, Wyatt Technology, USA) and UN detector (280 and 488 nm).
- DAWN-DSP-F light dispersion detector
- UN detector 280 and 488 nm
- the high molecular precursor was lyophilized. ⁇ Mw> and molecular weight distribution were determined by liquid chromatography, the content of hydrazide groups was determined spectroscopically by means of the T ⁇ BSA method. Doxorubicin was linked to the polymer and the conjugate was characterized under the same conditions as described in Example 1.
- a copolymer bearing hydrazide and maleimide groups (MI) (poly(HPMA-co-MA-X- ⁇ H ⁇ H 2 -co-MA-X- ⁇ H ⁇ H-MI)) in its side chains was prepared by partial modification of the hydrazide groups of polymeric precursor II containing 10 to 15 % mol of hydrazide groups using N-hydroxysuccinimidyl ester of maleimidyl propionic acid (SMP).
- SMP N-hydroxysuccinimidyl ester of maleimidyl propionic acid
- -SH groups into the antibody (immunoglobulin) molecule 15 mg of antibodies (polyclonal anti-thymocyte IgG) (0.1 ⁇ mol) were transferred into 1 ml phosphate buffer (0.05 M NaH 2 PO 4 /Na 2 HPO 4 ; 0.1 M NaCl; 0.01 M EDTA; pH 7.4) in a PD-10 column. 0.67 mg 2- iminothiolan (4 ⁇ mol) were dissolved in 50 ⁇ l DMF and added to the solution of intensely stirred antibodies. After 2.5 hours of stirring at laboratory temperature the product was isolated by gel filtration in a PD-10 column (phosphate buffer, pH 7.4). The level of antibody (immunoglobulin) modification was determined by a method utilizing the reaction of -SH groups with the Ellman reagent.
- conjugates were prepared by reacting antibodies into the molecules of which were aldehyde groups had been introduced by mild sodium periodate oxidation with hydrazide groups remaining after the reaction of polymeric precursor II with doxorubicin.
- oxidized antibodies 40 mg of antibodies (polyclonal anti-thymocyte IgG) were transferred to acetate buffer (0.02 M CH 3 COONa/CH 3 COOH; 0,15 M NaCl; pH 5) using a PD-10 column. A 0.1 M solution of NaIO 4 was prepared in the same buffer in the dark. The solutions of antibodies and periodate were mixed in the ratio of 4: 1 to reach the final concentrations of NaIO 4 and antibodies of 0.02 mol/1 and 9 mg/1, respectively. The reaction mixture was stirred at laboratory temperature in the dark for 2 hours after which 25 ⁇ l ethylene glycol per each ml of the reaction mixture were added.
- the oxidized antibodies (immunoglobulin) were purified and isolated by liquid chromatography in a PD-10 column.
- the concentration of antibodies (immunoglobulin) in the solution was determined by spectrophotometry.
- the number of aldehyde groups was determined by a method utilizing the reaction of aldehyde groups with the Lucifer Yellow CH dye.
- the conjugate was then concentrated and characterized in the same way as the other conjugates with antibodies (immunoglobulin).
- Human and rabbit non-specific immunoglobulin (IgG), polyclonal anti-thymocyte antibodies (ATG), monoclonal antibodies anti-Thy 1.2, anti-CD4, anti-CD 71, anti-BCLl, anti- CD4, anti-CD8, anti-CD 14 and other antibodies against tumor-associating antigens (anti-TAA) were used for conjugations with polymers.
- Fig. 5 shows the measurement results of the release rates of doxorubicin from polymers differing in the spacer compositions at a pH modeling the blood pH (7.4) and at a pH modeling the endosome or lysosome environment (pH 5 - 6).
- the concentration of linked Dox (0.5 mmol.l "1 ) was constant in 0.1 M acetate buffer (CH 3 COONa/CH 3 COOH, 0,05 M NaCl) in the experiments.
- the samples were incubated at 37 °C in the dark and 0.1 ml portions were taken in predefined intervals and analysed by means of HPLC after extraction of Do from the solution.
- cytotoxic activity The ability of polymeric conjugates to reduce cell division or proliferation of target cells is called a cytotoxic or cytostatic activity.
- the cytotoxic activity was detected in vitro by inhibition of incorporation of 3 H-thymidine to the target cell nuclei [Rihova et al, 2000]. Incorporation of thymidine and the activity of conjugates are indirectly proportional. Low incorporation of thymidine means high cytotoxic activity of tested substances.
- tumor lines mouse T leukemic line EL4, mouse B cellular leukemia BCL1, mouse B cellular lymphoma 38C13, primary human colorectal carcinoma SW 480, metastasizing human colorectal carcinoma SW 620, human colorectal carcinoma SW620 genetically modified by mouse gene for Thy 1.2 SW620/T
- mouse splenocytes stimulated by T-cellular mitogen, i.e. concanavalin A, and human peripheral lymphocytes were pipetted in the amounts of 1 x 10 4 - 5 x 10 5 (depending on the testing cell systems used) in growth medium RPMI 1640 into 96- well FB-tissue plates (NUNC, Denmark).
- microtitration tissue plates were incubated at 37 °C in the atmosphere of 5 % CO 2 for 24 to 72 hours. After completing the cultivation 1 ⁇ Ci of 3 H-thymidine was added to each well. After another five or six hours (depending on the testing system) the cells were collected (Tomtec cell collector) on a glass fiber filter (Filtermat, Wallac), dried and evaluated for radioactivity incorporated (MicroBeta Trilux, Wallac).
- ICso for non-targeted conjugates containing hydrolytically released doxorubicin ranged from 0.01 ⁇ g doxorubicin/ml to 1.41 ⁇ g doxorubicin/ml depending on the resistance (sensitivity to treatment of the target line used) and on the type of conjugate. It was confirmed that cytotoxicity is an exclusive property of conjugates containing hydrolytically released doxorubicin since a conjugate without the drug is not cytotoxic.
- mice of inbred strain C57BL/10 were subcutaneously transplanted with T-cellular lymphoma (EL4).
- the tumor cells were injected in the lower half of the back of experimental animals in the amount of 1 x 10 5 cells/mouse.
- the cell transplantation day was marked day 0.
- Polymeric conjugates with hydrolytically released doxorubicin were then administered intraperitoneally either on day 1, 3, 5, 7 and 9 (protective regimen), on day 10, 12, 14, 16 and 18 or on day 12, 14, 16, 18 and 20 (therapeutic regimen).
- the daily dose of doxorubicin was 50 ⁇ g/mouse.
- the conjugates significantly inhibited tumor growth and increased the number of long-term surviving experimental animals.
- doxorubicin had a very limited effect (maximum survival period of the experimental animals was 40 days as opposed to 35 days in the control group), administration of polymeric conjugates with hydrolytically released doxorubicin enabled long- term survival, i.e. more than 80 days, in 40 % and 20 % of mice in the protective regimen and therapeutic regimen, respectively.
- Mice of inbred strain Balb/c were i.p. transplanted with mouse B-cellular leukemia BCL1. The tumor cells were injected in the amount of 5 x 10 5 cells/mouse. The cell transplantation day was marked day 0.
- Polymeric conjugates with hydrolytically released doxorubicin were then administered intravenously on day 11, 13 and 17 (therapeutic regimen).
- the daily dose of doxorubicin was 100 ⁇ g/mouse.
- the tested conjugates had significant anti-tumor activity. While the control mice survived no longer than 40 days, 20 % of mice treated with the tested conjugates survived longer than 100 days and 10 % longer than 140 days.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02805243A EP1463529B9 (en) | 2001-12-20 | 2002-12-20 | Ph-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy |
DK02805243.9T DK1463529T5 (en) | 2001-12-20 | 2002-12-20 | PH-sensitive polymeric conjugates of a cancer-resistant anthracycline drug for targeted therapy |
KR10-2004-7009872A KR20040076874A (en) | 2001-12-20 | 2002-12-20 | pH-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy |
CZ2003605A CZ293886B6 (en) | 2002-12-20 | 2002-12-20 | pH sensitive polymeric conjugates of anthracycline cancerostatic for targeted therapy |
DE60233434T DE60233434D1 (en) | 2001-12-20 | 2002-12-20 | PH-SENSITIVE POLYMER CONJUGATES OF A CARCINOSTATIC ANTHRACYCLIN MEDICAMENT FOR TARGETED THERAPY |
SI200230855T SI1463529T1 (en) | 2001-12-20 | 2002-12-20 | Ph-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy |
JP2003554229A JP4718117B2 (en) | 2001-12-20 | 2002-12-20 | PH-sensitive polymer conjugates of anthracycline anticancer drugs for targeted therapy |
AT02805243T ATE439864T1 (en) | 2001-12-20 | 2002-12-20 | PH-SENSITIVE POLYMER CONJUGATES OF A CARCINOSTATIC ANTHRACYCLINE DRUG FOR TARGETED THERAPY |
AU2002366715A AU2002366715A1 (en) | 2001-12-20 | 2002-12-20 | Ph-sensitive polymeric conjugates of an anthracycline drug |
SK291-2004A SK2912004A3 (en) | 2001-12-20 | 2002-12-20 | pH-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy |
CA002470976A CA2470976A1 (en) | 2001-12-20 | 2002-12-20 | Ph-sensitive polymeric conjugates of an anthracycline drug |
HU0500541A HUP0500541A3 (en) | 2001-12-20 | 2002-12-20 | Ph-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy |
EA200400802A EA007353B1 (en) | 2001-12-20 | 2002-12-20 | Ph-sensitive polymeric conjugates of anthracycline cancerostatic active agents for targeted therapy |
US10/499,422 US7919076B2 (en) | 2001-12-20 | 2002-12-20 | PH-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CZ20014653A CZ293787B6 (en) | 2001-12-20 | 2001-12-20 | pH sensitive polymeric conjugates of anthracycline cancerostatic for targeted therapy |
CZPV4653-01 | 2001-12-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003053473A2 true WO2003053473A2 (en) | 2003-07-03 |
WO2003053473A3 WO2003053473A3 (en) | 2004-04-29 |
Family
ID=5473644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CZ2002/000070 WO2003053473A2 (en) | 2001-12-20 | 2002-12-20 | Ph-sensitive polymeric conjugates of an anthracycline drug |
Country Status (18)
Country | Link |
---|---|
US (1) | US7919076B2 (en) |
EP (2) | EP1463529B9 (en) |
JP (1) | JP4718117B2 (en) |
KR (1) | KR20040076874A (en) |
AT (1) | ATE439864T1 (en) |
AU (1) | AU2002366715A1 (en) |
CA (1) | CA2470976A1 (en) |
CZ (1) | CZ293787B6 (en) |
DE (1) | DE60233434D1 (en) |
DK (1) | DK1463529T5 (en) |
EA (1) | EA007353B1 (en) |
ES (1) | ES2331303T3 (en) |
HU (1) | HUP0500541A3 (en) |
PL (1) | PL216518B1 (en) |
PT (1) | PT1463529E (en) |
SI (1) | SI1463529T1 (en) |
SK (1) | SK2912004A3 (en) |
WO (1) | WO2003053473A2 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005007798A2 (en) * | 2003-07-16 | 2005-01-27 | Ústav makromolekulární chemie AVCR | Hydroxypropyl methacrylamide polymers and copolymers comprising reactive thiazoline-2-thione |
WO2007028347A2 (en) * | 2005-09-05 | 2007-03-15 | Zentiva, A.S. | Method for the preparation of polymeric conjugates of doxorubicin with ph- controlled release of the drug |
WO2007110003A2 (en) * | 2006-03-28 | 2007-10-04 | Zentiva, A.S. | Micellar carriers for drugs with anti-cancer activity |
WO2008017277A2 (en) * | 2006-08-09 | 2008-02-14 | Zentiva, A.S. | Polymeric conjugates of doxorubicin with ph-regulated release of the drug and a method of preparing |
WO2010045896A2 (en) * | 2008-10-23 | 2010-04-29 | Zentiva, K.S. | Polymeric composition with synergistic effect in treatment of tumour diseases |
US7790765B2 (en) | 2007-04-30 | 2010-09-07 | Arqule, Inc. | Hydroxy sulfonate of quinone compounds and their uses |
US7812051B2 (en) | 2004-08-11 | 2010-10-12 | Arqule, Inc. | Pharmaceutical compositions of β-lapachone and β-lapachone analogs with improved tumor targeting potential |
WO2011072627A3 (en) * | 2009-12-15 | 2011-08-11 | Ustav Makromolekularni Chemie Av Cr, V.V.I. | Dendritic high-molecular-weight polymer drug carriers and their conjugates with drugs especially for treatment of solid tumours |
EP2503332A3 (en) * | 2006-08-09 | 2013-11-13 | Sumitomo Bakelite Company, Ltd. | Sugar chain-capturing substance and use thereof |
US8614228B2 (en) | 2004-08-11 | 2013-12-24 | Arqule, Inc. | Quinone prodrug compositions and methods of use |
WO2021084087A1 (en) * | 2019-10-30 | 2021-05-06 | Cis Pharma Ag | Biocompatible polymeric drug carriers for delivering active agents |
US11801307B2 (en) | 2016-10-14 | 2023-10-31 | University Of Utah Research Foundation | Antibody-polymer-drug conjugates |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ298945B6 (en) | 2006-09-18 | 2008-03-19 | Zentiva, A. S. | Polymeric medicament and process for preparing thereof |
EP3069715A1 (en) | 2015-03-20 | 2016-09-21 | Salmon Pharma GmbH | Immediate release dosage forms of Atomoxetine |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8500209D0 (en) * | 1985-01-04 | 1985-02-13 | Ceskoslovenska Akademie Ved | Synthetic polymeric drugs |
-
2001
- 2001-12-20 CZ CZ20014653A patent/CZ293787B6/en not_active IP Right Cessation
-
2002
- 2002-12-20 DE DE60233434T patent/DE60233434D1/en not_active Expired - Lifetime
- 2002-12-20 ES ES02805243T patent/ES2331303T3/en not_active Expired - Lifetime
- 2002-12-20 EA EA200400802A patent/EA007353B1/en not_active IP Right Cessation
- 2002-12-20 CA CA002470976A patent/CA2470976A1/en not_active Abandoned
- 2002-12-20 AU AU2002366715A patent/AU2002366715A1/en not_active Abandoned
- 2002-12-20 WO PCT/CZ2002/000070 patent/WO2003053473A2/en active Application Filing
- 2002-12-20 JP JP2003554229A patent/JP4718117B2/en not_active Expired - Lifetime
- 2002-12-20 AT AT02805243T patent/ATE439864T1/en active
- 2002-12-20 SK SK291-2004A patent/SK2912004A3/en not_active Application Discontinuation
- 2002-12-20 EP EP02805243A patent/EP1463529B9/en not_active Expired - Lifetime
- 2002-12-20 PT PT02805243T patent/PT1463529E/en unknown
- 2002-12-20 DK DK02805243.9T patent/DK1463529T5/en active
- 2002-12-20 KR KR10-2004-7009872A patent/KR20040076874A/en not_active Application Discontinuation
- 2002-12-20 SI SI200230855T patent/SI1463529T1/en unknown
- 2002-12-20 PL PL370719A patent/PL216518B1/en not_active IP Right Cessation
- 2002-12-20 HU HU0500541A patent/HUP0500541A3/en unknown
- 2002-12-20 EP EP06025316A patent/EP1782833A3/en not_active Withdrawn
- 2002-12-20 US US10/499,422 patent/US7919076B2/en active Active
Non-Patent Citations (1)
Title |
---|
None |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005007798A3 (en) * | 2003-07-16 | 2006-04-06 | Ustav Makromolekularni Chemie | Hydroxypropyl methacrylamide polymers and copolymers comprising reactive thiazoline-2-thione |
WO2005007798A2 (en) * | 2003-07-16 | 2005-01-27 | Ústav makromolekulární chemie AVCR | Hydroxypropyl methacrylamide polymers and copolymers comprising reactive thiazoline-2-thione |
US7812051B2 (en) | 2004-08-11 | 2010-10-12 | Arqule, Inc. | Pharmaceutical compositions of β-lapachone and β-lapachone analogs with improved tumor targeting potential |
US8614228B2 (en) | 2004-08-11 | 2013-12-24 | Arqule, Inc. | Quinone prodrug compositions and methods of use |
WO2007028347A2 (en) * | 2005-09-05 | 2007-03-15 | Zentiva, A.S. | Method for the preparation of polymeric conjugates of doxorubicin with ph- controlled release of the drug |
WO2007028347A3 (en) * | 2005-09-05 | 2007-05-10 | Zentiva As | Method for the preparation of polymeric conjugates of doxorubicin with ph- controlled release of the drug |
EA015091B1 (en) * | 2005-09-05 | 2011-06-30 | ЗЕНТИВА, а.с. | A method for the preparation of polymeric conjugates of doxorubicin with ph-controlled release of the drug |
WO2007110003A2 (en) * | 2006-03-28 | 2007-10-04 | Zentiva, A.S. | Micellar carriers for drugs with anti-cancer activity |
WO2007110003A3 (en) * | 2006-03-28 | 2008-05-15 | Zentiva As | Micellar carriers for drugs with anti-cancer activity |
WO2008017277A2 (en) * | 2006-08-09 | 2008-02-14 | Zentiva, A.S. | Polymeric conjugates of doxorubicin with ph-regulated release of the drug and a method of preparing |
EP2503332A3 (en) * | 2006-08-09 | 2013-11-13 | Sumitomo Bakelite Company, Ltd. | Sugar chain-capturing substance and use thereof |
WO2008017277A3 (en) * | 2006-08-09 | 2008-03-27 | Zentiva As | Polymeric conjugates of doxorubicin with ph-regulated release of the drug and a method of preparing |
EP2799868A3 (en) * | 2006-08-09 | 2015-04-22 | Sumitomo Bakelite Co., Ltd. | Sugar chain-capturing substance and use thereof |
US9340651B2 (en) | 2006-08-09 | 2016-05-17 | Sumitomo Bakelite Company Limited | Sugar chain-capturing substance and use thereof |
US9714328B2 (en) | 2006-08-09 | 2017-07-25 | Sumitomo Bakelite Company, Ltd. | Sugar chain-capturing substance and use thereof |
US7790765B2 (en) | 2007-04-30 | 2010-09-07 | Arqule, Inc. | Hydroxy sulfonate of quinone compounds and their uses |
WO2010045896A3 (en) * | 2008-10-23 | 2010-08-12 | Zentiva, K.S. | Polymeric composition with synergistic effect in treatment of tumour diseases |
WO2010045896A2 (en) * | 2008-10-23 | 2010-04-29 | Zentiva, K.S. | Polymeric composition with synergistic effect in treatment of tumour diseases |
WO2011072627A3 (en) * | 2009-12-15 | 2011-08-11 | Ustav Makromolekularni Chemie Av Cr, V.V.I. | Dendritic high-molecular-weight polymer drug carriers and their conjugates with drugs especially for treatment of solid tumours |
US11801307B2 (en) | 2016-10-14 | 2023-10-31 | University Of Utah Research Foundation | Antibody-polymer-drug conjugates |
WO2021084087A1 (en) * | 2019-10-30 | 2021-05-06 | Cis Pharma Ag | Biocompatible polymeric drug carriers for delivering active agents |
Also Published As
Publication number | Publication date |
---|---|
DK1463529T3 (en) | 2009-10-19 |
CZ293787B6 (en) | 2004-07-14 |
PL216518B1 (en) | 2014-04-30 |
US20060057099A1 (en) | 2006-03-16 |
EP1463529A2 (en) | 2004-10-06 |
EP1463529B9 (en) | 2011-03-23 |
PL370719A1 (en) | 2005-05-30 |
HUP0500541A2 (en) | 2005-09-28 |
JP4718117B2 (en) | 2011-07-06 |
US7919076B2 (en) | 2011-04-05 |
EA007353B1 (en) | 2006-10-27 |
EP1782833A2 (en) | 2007-05-09 |
ATE439864T1 (en) | 2009-09-15 |
CZ20014653A3 (en) | 2003-08-13 |
ES2331303T9 (en) | 2011-08-18 |
AU2002366715A8 (en) | 2003-07-09 |
AU2002366715A1 (en) | 2003-07-09 |
KR20040076874A (en) | 2004-09-03 |
SI1463529T1 (en) | 2010-01-29 |
JP2005519044A (en) | 2005-06-30 |
ES2331303T3 (en) | 2009-12-29 |
PT1463529E (en) | 2009-11-03 |
DE60233434D1 (en) | 2009-10-01 |
EP1463529B1 (en) | 2009-08-19 |
EP1782833A3 (en) | 2008-03-19 |
WO2003053473A3 (en) | 2004-04-29 |
EA200400802A1 (en) | 2005-02-24 |
HUP0500541A3 (en) | 2011-08-29 |
DK1463529T5 (en) | 2011-06-27 |
CA2470976A1 (en) | 2003-07-03 |
SK2912004A3 (en) | 2004-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ulbrich et al. | Antibody-targeted polymer–doxorubicin conjugates with pH-controlled activation | |
Ulbrich et al. | Structural and chemical aspects of HPMA copolymers as drug carriers | |
Etrych et al. | New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties | |
Ulbrich et al. | HPMA copolymers with pH-controlled release of doxorubicin: in vitro cytotoxicity and in vivo antitumor activity | |
Kopeček et al. | HPMA copolymer–anticancer drug conjugates: design, activity, and mechanism of action | |
Kopeček et al. | HPMA copolymers: origins, early developments, present, and future | |
Etrych et al. | Biodegradable star HPMA polymer conjugates of doxorubicin for passive tumor targeting | |
Lu et al. | Design of novel bioconjugates for targeted drug delivery | |
US8603990B2 (en) | Grafted macromolecular conjugates of doxorubicin with anticancer activity and method of their preparation | |
EP1463529B1 (en) | Ph-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy | |
Etrych et al. | Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy | |
AU4094300A (en) | Amplification of folate-mediated targeting to tumor cells using polymers | |
Sirova et al. | Preclinical evaluation of linear HPMA-doxorubicin conjugates with pH-sensitive drug release: efficacy, safety, and immunomodulating activity in murine model | |
Duncan | N-(2-Hydroxypropyl) methacrylamide copolymer conjugates | |
ES2717836T3 (en) | Multifunctional drug delivery system based on polymic acid | |
JP2013513626A (en) | Dendritic high molecular weight polymer drug carriers and their conjugates with drugs, particularly for the treatment of solid tumors | |
CZ2006207A3 (en) | Medicament micellar carriers exhibiting antitumor activity | |
Pechar et al. | Poly (ethylene glycol)-doxorubicin conjugates with pH-controlled activation | |
Chytil et al. | Structural design and synthesis of polymer prodrugs | |
CZ2003605A3 (en) | pH sensitive polymeric conjugates of anthracycline cancerostatic for targeted therapy | |
Etrych et al. | Micellar and Antibody‐Targeted Polymer Therapeutics | |
Hoes et al. | Design of soluble conjugates of biodegradable polymeric carriers and adriamycin | |
SK9785A3 (en) | Polymeric remedy and preparation method thereof | |
Rihova et al. | HPMA-Anticancer Drug Conjugates | |
Ulbrich et al. | Synthetic polymer-drug conjugates for human therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2470976 Country of ref document: CA Ref document number: 2003554229 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020047009872 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002805243 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200400802 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2912004 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2962004 Country of ref document: SK |
|
WWP | Wipo information: published in national office |
Ref document number: 2002805243 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006057099 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10499422 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10499422 Country of ref document: US |